2025
Impact of Abatacept Inclusive Graft Versus Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy
Shah N, Ngwube A, Suresh T, Sowa A, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Dalal J, Grimley M, Jacobsohn D, Kamani N, Krajewski J, Krishnamurti L, Saini S, Skiles J, Shenoy S. Impact of Abatacept Inclusive Graft Versus Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplantation And Cellular Therapy 2025 PMID: 40543708, DOI: 10.1016/j.jtct.2025.06.015.Peer-Reviewed Original ResearchGraft-versus-host diseaseChronic graft-versus-host diseaseHematopoietic cell transplantationGraft-versus-host disease prophylaxisGVHD prophylaxisAbatacept groupCell transplantationIncidence of posterior reversible encephalopathy syndromeSeverity of graft-versus-host diseasePresence of graft-versus-host diseasePosterior reversible encephalopathy syndromeAllogeneic hematopoietic cell transplantationSibling donor hematopoietic cell transplantationDonor hematopoietic cell transplantationDonor-derived hematopoiesisImmune reconstitution patternsReduced intensity conditioningEvent-free survivalGraft-versus-hostHost disease prophylaxisReversible encephalopathy syndromeSystemic immune suppressionStem cell transplantationPrimary graft rejectionPediatric stem cell transplantation
2023
Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders
Ngwube A, Shah N, Schulz G, Krishnamurti L, Shenoy S. Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders. Blood 2023, 142: 4901. DOI: 10.1182/blood-2023-191145.Peer-Reviewed Original ResearchNon-malignant disordersPost-transplant cyclophosphamideSickle cell diseaseGVHD prophylaxisHematopoietic transplantationEvaluable patientsHaploidentical transplantationImmune suppressionBone marrowFirst year post-HCTGrade 1 acute GVHDChronic GVHD riskChronic skin GVHDGVHD-free survivalPost-transplant lymphoproliferationsRadiation-containing regimensYear post-HCTPhase 2 trialReduced intensity conditioningSerious infectious complicationsSystemic immune suppressionT-cell chimerismAllogeneic hematopoietic transplantationPrimary outcome measureStem cell boost
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply